mouse anti src Search Results


94
Cell Applications Inc mouse monoclonal anti src
Mouse Monoclonal Anti Src, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/Anti-Src%3A+Mouse+Src+Antibody/10__1158_slash_1541___7786__mcr___13___0435___t-49-28-31
Average 94 stars, based on 1 article reviews
mouse monoclonal anti src - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

92
R&D Systems goat anti src
Goat Anti Src, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/Human%2FMouse%2FRat+Src+Antibody/pm40132981-453-7-11
Average 92 stars, based on 1 article reviews
goat anti src - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier

93
R&D Systems antibodies for src af3389
Antibodies For Src Af3389, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/Human%2FMouse%2FRat+Src+Antibody/pmc08253092-59-12-27
Average 93 stars, based on 1 article reviews
antibodies for src af3389 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

93
R&D Systems mouse anti src mab6
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti Src Mab6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/Human%2FMouse%2FRat+Src+Antibody/pmc10569185-422-57-62
Average 93 stars, based on 1 article reviews
mouse anti src mab6 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

91
R&D Systems c src 327537 r d systems mab3389
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
C Src 327537 R D Systems Mab3389, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/Human%2FMouse%2FRat+Src+Antibody/pmc06135941__mmc1-42-81-83
Average 91 stars, based on 1 article reviews
c src 327537 r d systems mab3389 - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier

90
Becton Dickinson pe mouse anti-src
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Pe Mouse Anti Src, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/pe+mouse+anti+src/pmc05830886__mmc2-324-48-51
Average 90 stars, based on 1 article reviews
pe mouse anti-src - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Merck KGaA mouse monoclonal anti-src gd11
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Monoclonal Anti Src Gd11, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/mouse+monoclonal+anti+src/10__1074_slash_jbc__ra118__002784-210-12-17
Average 90 stars, based on 1 article reviews
mouse monoclonal anti-src gd11 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Merck KGaA mouse anti-avian src antibody clone ec10 (1:1,000 in pbs-t, 1% milk)
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti Avian Src Antibody Clone Ec10 (1:1,000 In Pbs T, 1% Milk), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/mouse+anti+avian+src+antibody+clone+ec10++1+1+000+in+pbs+t++1++milk+/pmc04485149-497-33-39
Average 90 stars, based on 1 article reviews
mouse anti-avian src antibody clone ec10 (1:1,000 in pbs-t, 1% milk) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
ImmunoGen Inc mouse anti-src (gd11)
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti Src (Gd11), supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/mouse+anti+src++gd11+/10__1128_slash_mcb__21__19__6387___6394__2001-41-20-17
Average 90 stars, based on 1 article reviews
mouse anti-src (gd11) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Oncogene Science Inc mouse anti-p60 v-src antibody
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti P60 V Src Antibody, supplied by Oncogene Science Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/mouse+anti+p60+v+src+antibody/pm09136964-36-0-6
Average 90 stars, based on 1 article reviews
mouse anti-p60 v-src antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
MBL International mouse anti-src (active), clone28
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti Src (Active), Clone28, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/mouse+anti+src++active+++clone28/pmc05225595-86-41-43
Average 90 stars, based on 1 article reviews
mouse anti-src (active), clone28 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Schering-Plough corporation anti-src (mouse monoclonal 327
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Anti Src (Mouse Monoclonal 327, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+src/anti+src++mouse+monoclonal+327/us08859500-467-12-20
Average 90 stars, based on 1 article reviews
anti-src (mouse monoclonal 327 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet: (A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.

(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Residue, Phospho-proteomics, Blocking Assay, Sample Prep, Control, Incubation, Recombinant, Western Blot, WST Assay, Proliferation Assay, Concentration Assay, Derivative Assay, Two Tailed Test

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet:

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Control, Recombinant, Virus, Bradford Assay, Staining, Colorimetric Assay, Software